Egetis is an innovative, unique and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment.
Aladote® a first-in-class drug candidate, being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed. A pivotal Phase IIb/III study for market approval in the US and EU is planned to be initiated. Aladote® has been granted Orphan Drug Designation (ODD) in the US. Eligible for ODD in the EU after Brexit, application under development.
Emcitate® a first-in-class drug candidate, being developed for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling. A first clinical trial (phase IIb) has been concluded with significant and clinically relevant results. The first patient has was dosed in December 2020 in the pivotal Phase IIb/III early intervention study for market approval in the US and EU. Emcitate® has been granted Orphan Drug Designation in the US and EU. US Rare Paediatric Disease Designation received in November 2020, eligible for Priority Review Voucher.
PledOx® a first-in-class drug candidate, being developed to reduce nerve damage associated with chemotherapy. PledOx® did not meet the efficacy endpoint in the prematurely closed Phase 3 POLAR program. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx® will be determined together with Solasia.
Egetis (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019.
- protects the liver
Prevents acute liver failure in paracetamol poisoning.
- restores signaling
Restores thyroid hormone signaling in cells with defect MCT8 transporter.
- protects the peripheral nerves
Protection against the nerve damage that often occurs in connection with chemotherapy.